The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 340:319-320 January 28, 1999 Number 4
NextNext

Treatment of Breast Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Hortobagyi, G. N.
-PubMed Citation
To the Editor: In his review of the treatment of breast cancer (Oct. 1 issue),1 Dr. Hortobagyi discusses the indications for adjuvant treatment. Table 4 of his article shows the selection of adjuvant systemic therapy according to the patient's age, estrogen-receptor status, and "level of risk." The levels of risk are listed as any, low, and moderate or high. How were the levels of risk defined?


Teresa Corcoran, M.D.
Cambridge Hospital
Cambridge, MA 02139

References

  1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984. [Free Full Text]
 
To the Editor: Dr. Hortobagyi notes that in women with breast cancer, "The combination of tamoxifen (or ovarian ablation for premenopausal women) and chemotherapy is more . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.